CAR T cell

History

The first chimeric receptors containing portions of an antibody and the T cell receptor were described in 1987 by Yoshihisa Kuwana et al., at Fujita Health University and Kyowa Hakko Kogyo, Co. Ltd., in Japan, and independently in 1989 by Gideon Gross and Zelig Eshhar at the Weizmann Institute in Israel. Originally termed "T-bodies", these early approaches combined an antibody's ability to specifically bind to diverse targets with the constant domains of the TCR-α or TCR-β proteins.

In 1991, chimeric receptors containing the intracellular signaling domain of CD3ζ were shown to activate T cell signaling by Arthur Weiss at the University of California, San Francisco. This work prompted CD3ζ intracellular domains to be added to chimeric receptors with antibody-like extracellular domains, commonly single-chain fraction variable (scFv) domains, as well as proteins such as CD4, subsequently termed first generation CARs.

A first generation CAR containing a CD4 extracellular domain and a CD3ζ intracellular domain was used in the first clinical trial of chimeric antigen receptor T cells by the biotechnology company Cell Genesys in the mid 1990s, allowing adoptively transferred T cells to target HIV infected cells, although it failed to show any clinical improvement. Similar early clinical trials of CAR T cells in solid tumors in the 1990s using first generation CARs targeting a solid tumor antigens such as MUC1 did not show long-term persistence of the transferred T cells or result in significant remissions.

In the early 2000s, co-stimulatory domains such as CD28 or 4-1BB were added to first generation CAR's CD3ζ intracellular domain. Termed second generation CARs, these constructs showed greater persistence and improved tumor clearance in pre-clinical models. Clinical trials in the early 2010s using second generation CARs targeting CD19, a protein expressed by normal B cells as well as B-cell leukemias and lymphomas, by investigators at the NCI, University of Pennsylvania, and Memorial Sloan Kettering Cancer Center demonstrated the clinical efficacy of CAR T cell therapies and resulted in complete remissions in many heavily pre-treated patients. These trials ultimately led in the US to the FDA's first two approvals of CAR T cells in 2017, those for tisagenlecleucel (Kymriah), marketed by Novartis originally for B-cell precursor acute lymphoblastic leukemia (B-ALL), and axicabtagene ciloleucel (Yescarta), marketed by Kite Pharma originally for diffuse large B-cell lymphoma (DLBCL). There are now six FDA-approved CAR T therapies.

Production

The first step in the production of CAR T-cells is the isolation of T cells from human blood. CAR T-cells may be manufactured either from the patient's own blood, known as an autologous treatment, or from the blood of a healthy donor, known as an allogeneic treatment. The manufacturing process is the same in both cases; only the choice of initial blood donor is different.

First, leukocytes are isolated using a blood cell separator in a process known as leukocyte apheresis. Peripheral blood mononuclear cells (PBMCs) are then separated and collected. The products of leukocyte apheresis are then transferred to a cell-processing center. In the cell processing center, specific T cells are stimulated so that they will actively proliferate and expand to large numbers. To drive their expansion, T cells are typically treated with the cytokine interleukin 2 (IL-2) and anti-CD3 antibodies. Anti-CD3/CD28 antibodies are also used in some protocols.

The expanded T cells are purified and then transduced with a gene encoding the engineered CAR via a retroviral vector, typically either an integrating gammaretrovirus (RV) or a lentiviral (LV) vector. These vectors are very safe in modern times due to a partial deletion of the U3 region. The new gene editing tool CRISPR/Cas9 has recently been used instead of retroviral vectors to integrate the CAR gene into specific sites in the genome.

The patient undergoes lymphodepletion chemotherapy prior to the introduction of the engineered CAR T-cells. The depletion of the number of circulating leukocytes in the patient upregulates the number of cytokines that are produced and reduces competition for resources, which helps to promote the expansion of the engineered CAR T-cells.

Delivery

Main article: Engineered CAR T cell delivery

Clinical applications

As of March 2019, there were around 364 ongoing clinical trials happening globally involving CAR T cells. The majority of those trials target blood cancers: CAR T therapies account for more than half of all trials for hematological malignancies. CD19 continues to be the most popular antigen target, followed by BCMA (commonly expressed in multiple myeloma). In 2016, studies began to explore the viability of other antigens, such as CD20. Trials for solid tumors are less dominated by CAR T, with about half of cell therapy-based trials involving other platforms such as NK cells.

Cancer

T cells are genetically engineered to express chimeric antigen receptors specifically directed toward antigens on a patient's tumor cells, then infused into the patient where they attack and kill the cancer cells. Adoptive transfer of T cells expressing CARs is a promising anti-cancer therapeutic, because CAR-modified T cells can be engineered to target potentially any tumor associated antigen.

Early CAR T cell research has focused on blood cancers. The first approved treatments use CARs that target the antigen CD19, present in B-cell-derived cancers such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). There are also efforts underway to engineer CARs targeting many other blood cancer antigens, including CD30 in refractory Hodgkin's lymphoma; CD33, CD123, and FLT3 in acute myeloid leukemia (AML); and BCMA in multiple myeloma. Aside from CD19, CARs targeting the multiple myeloma antigen B-cell maturation antigen (BCMA) have achieved the most clinical success so far. CARs targeting BCMA were initially reported by Robert Carpenter and James Kochenderfer et al. Anti-BCMA CAR T cells have now been tested in many clinical trials, and anti-BCMA CAR T-cell products have been approved by the U.S. Food and Drug Administration.

CAR T cells have also been found to be effective in treating glioblastoma. A single infusion is enough to show rapid tumor regression in a matter of days.

Solid tumors have presented a more difficult target. Identification of good antigens has been challenging: such antigens must be highly expressed on the majority of cancer cells, but largely absent on normal tissues. CAR T cells are also not trafficked efficiently into the center of solid tumor masses, and the hostile tumor microenvironment suppresses T cell activity.

Autoimmune disease

While most CAR T cell studies focus on creating a CAR T cell that can eradicate a certain cell population (for instance, CAR T cells that target lymphoma cells), other potential uses for this technology have emerged. T cells can mediate tolerance to antigens. A regulatory T cell outfitted with a CAR could confer tolerance to a specific antigen, which could be utilized in organ transplantation or rheumatologic diseases like lupus. It has been investigated as a treatment for ulcerative colitis and rheumatoid arthritis. Clinical trials have launched for systemic sclerosis, myositis and rheumatoid arthritis.

Approved therapies

Safety

There are serious side effects that result from CAR T-cells being introduced into the body, including cytokine release syndrome and neurotoxicity. Because it is a relatively new treatment, there are few data about the long-term effects of CAR T-cell therapy. There are still concerns about long-term patient survival, as well as pregnancy complications in female patients treated with CAR T-cells. Anaphylaxis may be a side effect, as the CAR is made with a foreign monoclonal antibody, and as a result provokes an immune response.

On-target/off-tumor recognition occurs when the CAR T-cell recognizes the correct antigen, but the antigen is expressed on healthy, non-pathogenic tissue. This results in the CAR T-cells attacking non-tumor tissue, such as healthy B cells that express CD19 causing B-cell aplasia. The severity of this adverse effect can vary but the combination of prior immunosuppression, lymphodepleting chemotherapy and on-target effects causing hypogammaglobulinaemia and prolonged cytopenias places patients at increased risk of serious infections. Comprehensive dental evaluation and treatment before CAR T-cell therapy is recommended for reducing the risk of oral and systemic infections during the neutropenic phase.

There is also the unlikely possibility that the engineered CAR T-cells will themselves become transformed into cancerous cells through insertional mutagenesis, due to the viral vector inserting the CAR gene into a tumor suppressor or oncogene in the host T cell's genome. Some retroviral (RV) vectors carry a lower risk than lentiviral (LV) vectors. However, both have the potential to be oncogenic. Genomic sequencing analysis of CAR insertion sites in T cells has been established for better understanding of CAR T-cell function and persistence in vivo.

Cytokine release syndrome

Main article: Cytokine release syndrome

The most common issue after treatment with CAR T-cells is cytokine release syndrome (CRS), a condition in which the immune system is activated and releases an increased number of inflammatory cytokines. The clinical manifestation of this syndrome resembles sepsis with high fever, fatigue, myalgia, nausea, capillary leakages, tachycardia and other cardiac dysfunction, liver failure, and kidney impairment. CRS occurs in almost all patients treated with CAR T-cell therapy; in fact, the presence of CRS is a diagnostic marker that indicates the CAR T-cells are working as intended to kill the cancer cells. The severity of CRS does not correlate with an increased response to the treatment, but rather higher disease burden. Severe cytokine release syndrome can be managed with immunosuppressants such as corticosteroids, and with tocilizumab, an anti-IL-6 monoclonal antibody. Early intervention using tocilizumab was shown to reduce the frequency of severe CRS in multiple studies without affecting the therapeutic effect of the treatment. A novel strategy aimed to ameliorate CRS is based on the simultaneous expression of an artificial non-signaling IL-6 receptor on the surface of CAR T-cells. This construct neutralizes macrophage-derived IL-6 through sequestration, thus decreasing the severity of CRS without interfering with the antitumor capability of the CAR T-cell itself.

Immune effector cell-associated neurotoxicity

Neurological toxicity is also often associated with CAR T-cell treatment. The underlying mechanism is poorly understood, and may or may not be related to CRS. Clinical manifestations include delirium, the partial loss of the ability to speak coherently while still having the ability to interpret language (expressive aphasia), lowered alertness (obtundation), and seizures. During some clinical trials, deaths caused by neurotoxicity have occurred. The main cause of death from neurotoxicity is cerebral edema. In a study carried out by Juno Therapeutics, Inc., five patients enrolled in the trial died as a result of cerebral edema. Two of the patients were treated with cyclophosphamide alone and the remaining three were treated with a combination of cyclophosphamide and fludarabine. In another clinical trial sponsored by the Fred Hutchinson Cancer Research Center, there was one reported case of irreversible and fatal neurological toxicity 122 days after the administration of CAR T-cells.

Hypokinetic movement disorder (parkinsonism, or movement and neurocognitive treatment emergent adverse events) has been observed with BCMA-chimeric antigen receptor (CAR) T-cell treatment for multiple myeloma.

Advantages/benefits

Tumor cells have the ability to evolve new mechanisms for evasion of the immune system after its initial response. Some of these methods include downregulating the expression of their Major Histocompatibility Complex, secreting immunosuppressive factors, or altering their antigen expression, limiting the ability of conventional T cells to recognize and kill them. CAR (Chimeric Antigen Receptor) T cells overcome this limitation by recognizing tumor antigens directly through their engineered receptor, therefore bypassing the need for MHC presentation.

In addition, CAR T Cell Therapy offers the included advantages of: Higher response rates in refractory cancers, longer term remission because they remain in the body for years, and they are a more personalized treatment approach because they use the body's own T cells.

Chimeric antigen receptor structure

Chimeric antigen receptors combine many facets of normal T cell activation into a single protein. They link an extracellular antigen recognition domain to an intracellular signalling domain, which activates the T cell when an antigen is bound. CARs are composed of four regions: an antigen recognition domain, an extracellular hinge region, a transmembrane domain, and an intracellular T cell signaling domain.

Antigen recognition domain

The antigen recognition domain is exposed to the outside of the cell, in the ectodomain portion of the receptor. It interacts with potential target molecules and is responsible for targeting the CAR T cell to any cell expressing a matching molecule.

The antigen recognition domain is typically derived from the variable regions of a monoclonal antibody linked together as a single-chain variable fragment (scFv). An scFv is a chimeric protein made up of the light (VL) and heavy (VH) chains of immunoglobins, connected with a short linker peptide. These VL and VH regions are selected in advance for their binding ability to the target antigen (such as CD19). The linker between the two chains consists of hydrophilic residues with stretches of glycine and serine in it for flexibility as well as stretches of glutamate and lysine for added solubility. Single domain antibodies (e.g. VH, VHH, VNAR) have been engineered and developed as antigen recognition domains in the CAR format due to their high transduction efficiency in T cells.

In addition to antibody fragments, non-antibody-based approaches have also been used to direct CAR specificity, usually taking advantage of ligand/receptor pairs that normally bind to each other. Cytokines, innate immune receptors, TNF receptors, growth factors, and structural proteins have all been successfully used as CAR antigen recognition domains.

Hinge region

The hinge, also called a spacer, is a small structural domain that sits between the antigen recognition region and the cell's outer membrane. An ideal hinge enhances the flexibility of the scFv receptor head, reducing the spatial constraints between the CAR and its target antigen. This promotes antigen binding and synapse formation between the CAR T cells and target cells. Hinge sequences are often based on membrane-proximal regions from other immune molecules including IgG, CD8, and CD28.

Transmembrane domain

The transmembrane domain is a structural component, consisting of a hydrophobic alpha helix that spans the cell membrane. It anchors the CAR to the plasma membrane, bridging the extracellular hinge and antigen recognition domains with the intracellular signaling region. This domain is essential for the stability of the receptor as a whole. Generally, the transmembrane domain from the most membrane-proximal component of the endodomain is used, but different transmembrane domains result in different receptor stability. The CD28 transmembrane domain is known to result in a highly expressed, stable receptor.

Using the CD3-zeta transmembrane domain is not recommended, as it can result in incorporation of the artificial TCR into the native TCR.

Intracellular T cell signaling domain

Normal T cell activation relies on the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) present in the cytoplasmic domain of CD3-zeta. To mimic this process, CD3-zeta's cytoplasmic domain is commonly used as the main CAR endodomain component. Other ITAM-containing domains have also been tried, but are not as effective.

T cells also require co-stimulatory molecules in addition to CD3 signaling in order to persist after activation. For this reason, the endodomains of CAR receptors typically also include one or more chimeric domains from co-stimulatory proteins. Signaling domains from a wide variety of co-stimulatory molecules have been successfully tested, including CD28, CD27, CD134 (OX40), and CD137 (4-1BB).

The intracellular signaling domain used defines the generation of a CAR T cell. First generation CARs include only a CD3-zeta cytoplasmic domain. Second generation CARs add a co-stimulatory domain, like CD28 or 4-1BB. The involvement of these intracellular signaling domains improve T cell proliferation, cytokine secretion, resistance to apoptosis, and in vivo persistence. Third generation CARs combine multiple co-stimulatory domains, such as CD28-41BB or CD28-OX40, to augment T cell activity. Preclinical data show the third-generation CARs exhibit improved effector functions and better in vivo persistence as compared to second-generation CARs.

Research directions

Antigen recognition

Although the initial clinical remission rates after CAR T cell therapy in all patients are as high as 90%, long-term survival rates are much lower. The cause is typically the emergence of leukemia cells that do not express CD19 and so evade recognition by the CD19–CAR T cells, a phenomenon known as antigen escape. Preclinical studies developing CAR T cells with dual targeting of CD19 plus CD22 or CD19 plus CD20 have demonstrated promise, and trials studying bispecific targeting to circumvent CD19 down-regulation are ongoing.

In 2018, a version of CAR was developed that is referred to as SUPRA CAR, or split, universal, and programmable. Multiple mechanisms can be deployed to finely regulate the activity of SUPRA CAR, which limits overactivation. In contrast to the traditional CAR design, SUPRA CAR allows targeting of multiple antigens without further genetic modification of a person's immune cells.

Treatment of antigenically heterogeneous tumors can be achieved by administration of a mixture of the desired antigen-specific adaptors.

CAR T function

Fourth generation CARs (also known as TRUCKs or armored CARs) further add factors that enhance T cell expansion, persistence, and anti-tumoral activity. This can include cytokines, such is IL-2, IL-5, IL-12 and co-stimulatory ligands.

Control mechanisms

Adding a synthetic control mechanism to engineered T cells allows doctors to precisely control the persistence or activity of the T cells in the patient's body, with the goal of reducing toxic side effects. The major control techniques trigger T cell death or limit T cell activation, and often regulate the T cells via a separate drug that can be introduced or withheld as needed.

;Suicide genes: Genetically modified T cells are engineered to include one or more genes that can induce apoptosis when activated by an extracellular molecule. Herpes simplex virus thymidine kinase (HSV-TK) and inducible caspase 9 (iCasp9) are two types of suicide genes that have been integrated into CAR T cells. In the iCasp9 system, the suicide gene complex has two elements: a mutated FK506-binding protein with high specificity to the small molecule rimiducid/AP1903, and a gene encoding a pro-domain-deleted human caspase 9. Dosing the patient with rimiducid activates the suicide system, leading to rapid apoptosis of the genetically modified T cells. Although both the HSV-TK and iCasp9 systems demonstrate a noticeable function as a safety switch in clinical trials, some defects limit their application. HSV-TK is virus-derived and may be immunogenic to humans. It is also currently unclear whether the suicide gene strategies will act quickly enough in all situations to halt dangerous off-tumor cytotoxicity. ;Dual-antigen receptor: CAR T cells are engineered to express two tumor-associated antigen receptors at the same time, reducing the likelihood that the T cells will attack non-tumor cells. Dual-antigen receptor CAR T cells have been reported to have less intense side effects. An in vivo study in mice shows that dual-receptor CAR T cells effectively eradicated prostate cancer and achieved complete long-term survival. ;ON-switch and OFF-switch: In this system, CAR T cells can only function in the presence of both tumor antigen and a benign exogenous molecule. To achieve this, the CAR T cell's engineered chimeric antigen receptor is split into two separate proteins that must come together in order to function. The first receptor protein typically contains the extracellular antigen binding domain, while the second protein contains the downstream signaling elements and co-stimulatory molecules (such as CD3ζ and 4-1BB). In the presence of an exogenous molecule (such as a rapamycin analog), the binding and signaling proteins dimerize together, allowing the CAR T cells to attack the tumor. Human EGFR truncated form (hEGFRt) has been used as an OFF-switch for CAR T cells using cetuximab. ;Bispecific molecules as switches: Bispecific molecules target both a tumor-associated antigen and the CD3 molecule on the surface of T cells. This ensures that the T cells cannot become activated unless they are in close physical proximity to a tumor cell. The anti-CD20/CD3 bispecific molecule shows high specificity to both malignant B cells and cancer cells in mice. FITC is another bifunctional molecule used in this strategy. FITC can redirect and regulate the activity of the FITC-specific CAR T cells toward tumor cells with folate receptors.

Manufacturing

Due to high costs, researchers are seeking less expensive ways to modify cells. In situ manufacturing eliminates expensive steps. Delivery systems include immune-evasive lentiviral vectors and targeted lipid nanoparticles.

Another approach exploits bioinstructive materials.

Shortening or eliminating the activation and expansion steps is another cost reduction strategy.

Alternative activating domains

Recent advancements in CAR T-cell therapy have focused on alternative activating domains to enhance efficacy and overcome resistance in solid tumors. For instance, Toll-like receptor 4 (TLR4) signaling components can be incorporated into CAR constructs to modulate cytokine production and boost T-cell activation and proliferation, leading to enhanced CAR T-cell expansion and persistence. Similarly, the FYN kinase, a member of the Src family kinases involved in T-cell receptor signaling, can be integrated to improve the signaling cascade within CAR T-cells, resulting in better targeting and elimination of cancer cells. Additionally, KIR-based CARs (KIR-CAR), which use the transmembrane and intracellular domains of the activating receptor KIR2DS2 combined with the DAP-12 signaling adaptor, have shown improved T-cell proliferation and antitumor activity. These strategies, including the use of nonconventional costimulatory molecules like MyD88/CD40, highlight the innovative approaches being taken to optimize CAR T-cell therapies for more effective cancer treatments.

Economics

The cost of CAR T cell therapies has been criticized, with the initial costs of tisagenlecleucel and axicabtagene ciloleucel at $375,000 and $475,000, respectively. The high cost of CAR T therapies is due to complex cellular manufacturing in specialized good manufacturing practice (GMP) facilities as well as the high level of hospital care necessary after CAR T cells are administered due to risks such as cytokine release syndrome. In the United States, CAR T cell therapies are covered by Medicare and by many but not all private insurers. Manufacturers of CAR T cells have developed alternative payment programs due to the high cost of CAR T therapy, such as by requiring payment only if the CAR T therapy induces a complete remission by a certain time point after treatment.

Additionally, CAR T cell therapies are not available worldwide yet. CAR T cell therapies have been approved in China, Australia, Singapore, the United Kingdom, and some European countries. In February 2022 Brazil approved tisagenlecleucel (Kymriah) treatment.

As a promising strategy to reduce complexity and cost of CAR T-cell therapy, in vivo CAR T-cell therapy has recently emerged. This approach entails the direct delivery of CAR-encoding genetic material into a patient's T-cells in situ, typically via functionalised viral vectors or targeted nanocarriers, eliminating the necessity for ex vivo cell harvesting, separation, modification, expansion and reinfusion. Various delivery platforms are currently under investigation, including lipid nanoparticles, exosomes, and polymer-based nanocarriers, as well as viral vectors such as lentivirus, retrovirus, and adeno-associated virus (AAV) by universities like the Columbia Initiative in Cell Engineering and Therapy or biotech companies like Interius BioTherapeutics, Umoja Biopharma, or EsoBiotec. Porentially related risks involve challenges with precise T cell targeting, off-tumour on-target (OTOT) toxicities or with sustained CAR expression. However, in vivo CAR T therapy might mitigate some of the associated risks of systemic toxicities of classic ex vivo CAR T therapy like cytokine release syndrome (CRS) or Immune effector cell-associated neurotoxicity (ICANS). Besides an estimated reduction in costs by "an order of magnitude" compared to classic ex vivo CAR therapy, the biggest potential advantage of in vivo CAR T-cell transfection is a reduction of timelines, as 20% of patients die before their CAR T-cell therapy has been produced in the USA.

References

References

1. (July 12, 2017). "New Gene Therapy for Cancer Offers Hope to Those With No Options Left". NBC News.
2. (August 2015). "Engineering CAR-T cells: Design concepts". Trends in Immunology.
3. (September 2017). "Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts". EMBO Molecular Medicine.
4. (December 2015). "Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy". Oncotarget.
5. (December 2020). "Engineering better chimeric antigen receptor T cells". Experimental Hematology & Oncology.
6. (December 1987). "Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions". Biochemical and Biophysical Research Communications.
7. (February 1989). "Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity". Transplantation Proceedings.
8. (October 2017). "Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy". The New England Journal of Medicine.
9. (December 1989). "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity". Proceedings of the National Academy of Sciences of the United States of America.
10. (1996). "The T-body approach: potential for cancer immunotherapy". Springer Seminars in Immunopathology.
11. (March 1991). "The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways". Cell.
12. (December 1996). "T-cell gene therapy". Current Opinion in Biotechnology.
13. (July 2018). "Chimeric Antigen Receptor Therapy". The New England Journal of Medicine.
14. (February 2020). "The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19". Cytotherapy.
15. (January 2003). "Targeting tumours with genetically enhanced T lymphocytes". Nature Reviews. Cancer.
16. Center for Biologics Evaluation and Research. (2022-03-01). "Approved Cellular and Gene Therapy Products". FDA.
17. (2014-03-05). "Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors". Molecular Therapy: Methods & Clinical Development.
18. (2022). "Single-Domain Antibodies".
19. (June 2017). "Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma". Cancer Science.
20. (July 2016). "Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer". EMBO Molecular Medicine.
21. (June 2019). "Therapeutic gene editing in haematological disorders with CRISPR/Cas9". British Journal of Haematology.
22. (December 2006). "Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?". Nature Clinical Practice. Oncology.
23. (October 2019). "The global pipeline of cell therapies for cancer". Nature Reviews. Drug Discovery.
24. Brudno and Kochenderfer. Chimeric antigen receptor T cell therapies for lymphoma. ''Nature Reviews Clinical Oncology''. 2018. 15: 31-46.
25. Mikkilineni and Kochenderfer. Chimeric antigen receptor T-cell therapies for multiple myeloma. ''Blood''. 2017. 130: 2594-602
26. (2016). "CAR T Cell Therapy: A Game Changer in Cancer Treatment". Journal of Immunology Research.
27. (November 2011). "Time to put the CAR-T before the horse". Blood.
28. (July 2021). "Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3". Pharmacology & Therapeutics.
29. (2022). "Hepatobiliary Cancers: Translational Advances and Molecular Medicine". Advances in Cancer Research.
30. (November 2010). "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19". Blood.
31. (February 2015). "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor". Journal of Clinical Oncology.
32. (February 2019). "Driving CAR T cell translation forward". Science Translational Medicine.
33. (2021). "CAR T cell therapies for patients with multiple myeloma". National Library of Medicine.
34. (15 April 2013). "B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma". Clinical Cancer Research.
35. (29 September 2016). "T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma". Blood.
36. (1 May 2019). "Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma". The New England Journal of Medicine.
37. (24 July 2021). "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study". The Lancet.
38. (9 August 2024). "FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma". U.S. FDA.
39. (2024-04-11). "Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma". New England Journal of Medicine.
40. (February 2017). "The Principles of Engineering Immune Cells to Treat Cancer". Cell.
41. (2017-08-08). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America.
42. (2021-06-15). "CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice". Cell Reports. Medicine.
43. (May 2008). "Regulatory T cells and immune tolerance". Cell.
44. (2018). "Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance". Frontiers in Immunology.
45. (August 2021). "CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus". The New England Journal of Medicine.
46. (3 June 2024). "Chimeric antigen receptor T cell therapy for autoimmune disease". Nature Reviews Immunology.
47. Fieldhouse, Rachel. (2025-11-26). "'They don't have symptoms': CAR-T therapies send autoimmune diseases into remission". Nature.
48. (2017-08-30). "Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice".
49. "Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)".
50. (2019-05-15). "Novartis gets approval to sell Kymriah in Japan for $306,000".
51. (2019-04-05). "KYMRIAH (tisagenlecleucel)".
52. "FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma".
53. "Novartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma".
54. Center for Biologics Evaluation and Research. (2017-10-18). "FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma". FDA.
55. "Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy".
56. "Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China".
57. (2022-12-22). "Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma".
58. Center for Biologics Evaluation and Research. (2020-05-28). "YESCARTA (axicabtagene ciloleucel)". FDA.
59. "Kite's CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma".
60. "U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy".
61. "Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma".
62. Center for Biologics Evaluation and Research. (2021-03-04). "TECARTUS (brexucabtagene autoleucel)". FDA.
63. Center for Biologics Evaluation and Research. (2021-03-04). "TECARTUS (brexucabtagene autoleucel)". FDA.
64. "U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma".
65. "CAR T Cell Therapy Breyanzi® Approved as Relapsed or Refractory Large B-cell Lymphoma Second-Line Therapy in Japan".
66. Center for Biologics Evaluation and Research. (2022-06-24). "FDA D.I.S.C.O. Burst Edition: FDA approval of Breyanzi (lisocabtagene maraleucel) for second-line treatment of large B-cell lymphoma". FDA.
67. Center for Biologics Evaluation and Research. (2021-03-27). "ABECMA (idecabtagene vicleucel)". FDA.
68. Center for Biologics Evaluation and Research. (2022-03-21). "CARVYKTI". FDA.
69. Research, Center for Drug Evaluation and. (2024-11-08). "FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia". FDA.
70. (20 May 2024). "Current understanding and management of CAR T cell-associated toxicities". Nature Reviews Clinical Oncology.
71. (2016). "Toxicity and management in CAR T-cell therapy". Molecular Therapy: Oncolytics.
72. (25 February 2021). "Immunogenicity of CAR T cells in cancer therapy". Nature Reviews Clinical Oncology.
73. (June 2021). "CAR-T cell therapy and infection: a review". Expert Review of Anti-Infective Therapy.
74. (September 2025). "MASCC/ISOO Clinical Practice Statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy". Supportive Care in Cancer.
75. (February 2007). "Cytokine-release syndrome: overview and nursing implications". Clinical Journal of Oncology Nursing.
76. (July 2014). "Current concepts in the diagnosis and management of cytokine release syndrome". Blood.
77. (2022-11-29). "Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment". Transfusion Medicine and Hemotherapy.
78. (December 2019). "Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy". Blood.
79. (April 2020). "Chimeric antigen receptor-T cells with cytokine neutralizing capacity". Blood Advances.
80. (June 2016). "Toxicities of chimeric antigen receptor T cells: recognition and management". Blood.
81. "Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)". ClinicalTrials.gov.
82. (June 2016). "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients". The Journal of Clinical Investigation.
83. Gust, Juliane. (October 5, 2023). "BCMA-CAR T-cell treatment–associated parkinsonism". Blood.
84. (6 December 2013). "CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers".
85. (July 2019). "T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance". Immunological Reviews.
86. (January 2014). "Design and development of therapies using chimeric antigen receptor-expressing T cells". Immunological Reviews.
87. (2017-06-24). "Engineering CAR-T cells". Biomarker Research.
88. (May 2015). "Chimeric fusion proteins used for therapy: indications, mechanisms, and safety". Drug Safety.
89. (August 2017). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America.
90. (June 2020). "Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice". Gastroenterology.
91. (2023-04-08). "The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer". Nature Communications.
92. (2023-02-01). "Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC". Hepatology Communications.
93. (2022-03-17). "A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer". Molecular Therapy: Oncolytics.
94. (February 2015). "The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity". Cancer Immunology Research.
95. (March 2017). "Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells". Journal of Hematology & Oncology.
96. (June 2010). "The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex". Journal of Immunology.
97. (2011). "Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes". Journal of Cancer.
98. (April 2013). "The basic principles of chimeric antigen receptor design". Cancer Discovery.
99. (March 8, 2018). "A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology.". labiotech.
100. (2020). "Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology". Annual Review of Cancer Biology.
101. (May 2018). "Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses". Cell.
102. [http://endocyte.com/technology/smdc/ SMDC technology]. {{Webarchive. link. (2016-03-27 ENDOCYTE)
103. (April 19, 2016). "Endocyte announces promising preclinical data for application of SMDC technology in CAR T cell therapy in late-breaking abstract at American Association for Cancer Research (AACR) annual meeting 2016". Endocyte.
104. (March 2018). "CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity". Molecular Therapy: Oncolytics.
105. (2015). "TRUCKs: the fourth generation of CARs". Expert Opinion on Biological Therapy.
106. (January 2017). "A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy". Journal of Hematology & Oncology.
107. (June 1997). "HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia". Science.
108. (October 2007). "Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes". Blood.
109. (February 1996). "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients". Nature Medicine.
110. (January 2002). "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor". Nature Biotechnology.
111. (October 2012). "Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling". Journal of Clinical Immunology.
112. (October 2015). "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor". Science.
113. (June 2013). "Targeting T cells to tumor cells using bispecific antibodies". Current Opinion in Chemical Biology.
114. (May 2015). "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies". Science Translational Medicine.
115. (October 2013). "Bispecific small molecule-antibody conjugate targeting prostate cancer". Proceedings of the National Academy of Sciences of the United States of America.
116. (2025-11-18). "From bench to body: In vivo CAR engineering in the clinic". Cell Reports Medicine.
117. Ledford, Heidi. (2023-12-20). "Cancer-fighting CAR-T cells could be made inside body with viral injection". Nature.
118. (2017-04-17). "In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers". Nature Nanotechnology.
119. (2019-10-10). "''In vivo'' generated human CAR T cells eradicate tumor cells". OncoImmunology.
120. (2022-03-24). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology.
121. (February 2022). "Rapid manufacturing of non-activated potent CAR T cells". Nature Biomedical Engineering.
122. (2023-10-23). "Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy". Frontiers in Immunology.
123. (June 2024). "Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors". Molecular Therapy: Oncology.
124. (2022-06-01). "The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy". Medicine in Drug Discovery.
125. (2023-02-21). "CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance". Cell Reports. Medicine.
126. (July 2015). "Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors". Cancer Immunology Research.
127. (2022-09-25). "First-in-Human Trial to Assess KIR-CAR T-Cell Therapy in MSLN+ Solid Tumors".
128. (May 2014). "152. A Chimeric Antigen Receptor (CARs) Based Upon a Killer Immunoglobulin-Like Receptor (KIR) Triggers Robust Cytotoxic Activity in Solid Tumors". Molecular Therapy.
129. (2024-03-22). "Abstract 6332: Evaluating the relationship of affinity, functional avidity, and in vivo potency in KIR-CAR T cells". Cancer Research.
130. (2020-11-05). "MyD88/CD40 signaling retains CAR T cells in a less differentiated state". JCI Insight.
131. (September 2019). "Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies". Leukemia.
132. (April 2020). "Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma". JAMA Network Open.
133. "Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)".
134. "CAR T-cell Therapy: An Update on Coverage and Reimbursement - Hematology.org".
135. (September 2020). "Value and affordability of CAR T-cell therapy in the United States". Bone Marrow Transplantation.
136. (25 November 2021). "Which countries is CAR T-cell therapy available in? {{!}} SingleUseSupport". SingleUseSupport.
137. (2022-02-23). "Anvisa aprova produto de terapia avançada para tratamento de câncer".
138. (1 August 2024). "Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment". EBioMedicine, the Lancet.
139. (29 May 2025). "Cancer-fighting immune cells could soon be engineered inside our bodies". Nature.
140. "'How do you decide?': The CAR-T cell shortage is forcing impossible decisions".